Channing J. Paller

Also affiliated with Johns Hopkins Medicine, VA Boston Healthcare System, Sidney Kimmel Cancer Center, Sidney Kimmel Comprehensive Cancer Center, University of Baltimore

MedicineNursingBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.225Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons

Molecular Case Studies(2023)10.1101/mcs.a006298

Top 62%

0.225DataRank

Top 62%3 citations

Aarti Venkat, Danne C. Elbers, John Bihn, Mary T. Brophy, Nhan V. Do +9 more

Papers

Driven by 25 papers — median percentile 38. Top paper: “Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial”.

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Nature Communications(2024)10.1038/s41467-023-44514-2

N/A

1.3DataRank · unranked

49 citations

Mary‐Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi +15 more

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy

European Journal of Cancer(2020)10.1016/j.ejca.2020.11.043

N/A

1.2DataRank · unranked

47 citations

Hao Wang, Su J. Lim ScM, Irina Rifkind, Nduku Ngomba, John T. Isaacs +10 more

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer(2020)10.1186/s12885-020-07000-2

N/A

1.1DataRank · unranked

32 citations

Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan +26 more

Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations

Scientific Reports(2020)10.1038/s41598-020-60456-x

N/A

0.926DataRank · unranked

23 citations

Vy Tran, Mikhail Maertens, André Kleensang, Thomas Luechtefeld, Thomas Härtung +2 more

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited

European Urology(2021)10.1016/j.eururo.2020.12.040

N/A

0.692DataRank · unranked

100 citations

Kim Van der Eecken, Ryan Phillips, Neil R. Parikh, Pedro Isaacsson Velho, Tamara L. Lotan +19 more

Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.28444

N/A

0.562DataRank · unranked

14 citations

Lin Wang, June K. Corrigan, Deborah Lang, Michelle Lee, Nhan V. Do +4 more

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0225

N/A

0.554DataRank · unranked

18 citations

Marianna Zahurak, Adel Mandl, Nicole A. Metri, Aliya Lalji, Elisabeth I. Heath +18 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0.449DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0.345DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5001

N/A

0.312DataRank · unranked

7 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara +15 more

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5087

N/A

0.241DataRank · unranked

4 citations

Benjamin A. Teply, Su Jin Lim, Hao Wang, Shifeng Mao, William Kevin Kelly +10 more

Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons

Molecular Case Studies(2023)10.1101/mcs.a006298

Top 62%

0.225DataRank

Top 62%3 citations

Aarti Venkat, Danne C. Elbers, John Bihn, Mary T. Brophy, Nhan V. Do +9 more

Author Correction: Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations

Scientific Reports(2020)10.1038/s41598-020-66767-3

N/A

0.208DataRank · unranked

3 citations

Vy Tran, Mikhail Maertens, André Kleensang, Thomas Luechtefeld, Thomas Härtung +2 more

Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.63

N/A

0.165DataRank · unranked

2 citations

Catherine H. Marshall, Rebeca Lozano, Petros Grivas, Celestia S. Higano, Tamara L. Lotan +11 more

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.116

N/A

0.165DataRank · unranked

2 citations

Ryan Phillips, William T. Shi, Su Jin Lim, Emmanuel S. Antonarakis, Steven P. Rowe +15 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0.165DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

Integrative Oncology for Prostate Cancer: A Narrative Review

Seminars in Radiation Oncology(2026)10.1016/j.semradonc.2026.151031

N/A

0.104DataRank · unranked

1 citations

Nicole A. Metri, Robert U. Newton, Divya Ajay, Eleanor M. Walker, Channing J. Paller +1 more

RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5576

N/A

0.104DataRank · unranked

1 citations

Hao Wang, Michael T. Schweizer, Michael A. Carducci, Channing J. Paller, Benjamin A. Teply +5 more

1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2781

N/A

0DataRank · unranked

0 citations

M.L. Zahurek, Adel Mandl, Michelle A. Rudek, Elisabeth I. Heath, Catherine H. Marshall +13 more

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.23.533944

N/A

0DataRank · unranked

3 citations

Peter T. Gallagher, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer K. McCann, Emanuela Dylgjeri +8 more

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer

The Prostate(2024)10.1002/pros.24712

N/A

0DataRank · unranked

17 citations

Lukasz P. Gondek, В. Даниэльс, Changxue Lu, Sergiu Paşca, Jiajun Xie +7 more

Therapeutic Approaches to Targeting Androgen Receptor Splice Variants

Cells(2024)10.3390/cells13010104

N/A

0DataRank · unranked

14 citations

Jun Luo, Channing J. Paller, Mayuko Kanayama, В. Даниэльс

Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab071

N/A

0DataRank · unranked

23 citations

Channing J. Paller, Hwanhee Hong, Lori Rosman, Anthony De Felice, Otis W. Brawley +2 more

Clinical Research Network: JHCRN Infrastructure and Lessons Learned

Clinical and Translational Science(2025)10.1111/cts.70123

N/A

0DataRank · unranked

3 citations

Gayane Yenokyan, Robert L. Joyner, Melissa Gerstenhaber, Mary Alderfer, Erika Siegrist +9 more

On the Black–White Disparity in Prostate Cancer Mortality

JNCI Cancer Spectrum(2021)10.1093/jncics/pkab094

N/A

0DataRank · unranked

0 citations

Channing J. Paller, Otis W. Brawley

Channing J. Paller

Indexed papers

Top data-sharing exemplar

Papers